| Condition | Cannabinoid-Based Drug | Outcomes for Pain | Outcomes for Depression and Anxiety | FDA Approved |
| Lennox-gastaut syndrome | Epidiolex® | ↓Pain, epileptic episodes | ↓Anxiety | Yes |
| Dravet syndrome | Epidiolex® | ↓Pain, epileptic episodes | ↓Anxiety | Yes |
| HIV | Marijuana | ↓Muscle, nerve pain | ↓Anxiety | No |
| Cancer | Nabilone | ↓Pain score | ↓Overall stress | No |
| Fibromyalgia | Nabilone | ↓Pain | ↓Anxiety | No |
| Psychiatric disorders | Nabilone | ↓Pain | ↓Post-traumatic stress disorder symptoms | No |
| Chronic central neuropathic pain | Δ9-THC | ↓Pain and pain intensity | ↓Anxiety | No |
| Diabetic peripheral neuropathy | Sativex (Δ9-THC, cannabidiol) | ↓Pain | ↑Quality of life | No |